Evidence map›Paper›PMID 28673870›Full record

ReviewProgress in retinal and eye research2017

Fluorescence lifetime imaging ophthalmoscopy.

Chantal Dysli, Sebastian Wolf, Mikhail Y Berezin, Lydia Sauer, Martin Hammer, Martin S Zinkernagel

Open access · hybridAbstract readReview
In one paragraph

Review in Progress in retinal and eye research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 1 pooled it
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 1 synthesis or guideline pooled it, 193 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Macular telangiectasia type 2: An update.The Journal of international medical research · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Chantal DysliDepartment of Ophthalmology and Department of Clinical Research, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Sebastian WolfDepartment of Ophthalmology and Department of Clinical Research, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Mikhail Y BerezinDepartment of Radiology, Washington University School of Medicine, St. Louis, Missouri, United States.
Lydia SauerDepartment of Ophthalmology, University Hospital Jena, Jena, Germany.
Martin HammerDepartment of Ophthalmology, University Hospital Jena, Jena, Germany.
Martin S ZinkernagelDepartment of Ophthalmology and Department of Clinical Research, Inselspital, Bern University Hospital, University of Bern, Switzerland. Electronic address: m.zinkernagel@gmail.com.
University of Bern · CHJena University Hospital · DEWashington University in St. Louis · US

Funding

ASSESSMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY WITH ACTIVABLE PROBESR21CA198419 · NCI · WASHINGTON UNIVERSITY · PI BEREZIN, MIKHAIL Y. · 2015 to 2016
$365k
NCI NIH HHS R21 CA198419
6 · The paper itself

Abstract

Imaging techniques based on retinal autofluorescence have found broad applications in ophthalmology because they are extremely sensitive and noninvasive. Conventional fundus autofluorescence imaging measures fluorescence intensity of endogenous retinal fluorophores. It mainly derives its signal from lipofuscin at the level of the retinal pigment epithelium. Fundus autofluorescence, however, can not only be characterized by the spatial distribution of the fluorescence intensity or emission spectrum, but also by a characteristic fluorescence lifetime function. The fluorescence lifetime is the average amount of time a fluorophore remains in the excited state following excitation. Fluorescence lifetime imaging ophthalmoscopy (FLIO) is an emerging imaging modality for in vivo measurement of lifetimes of endogenous retinal fluorophores. Recent reports in this field have contributed to our understanding of the pathophysiology of various macular and retinal diseases. Within this review, the basic concept of fluorescence lifetime imaging is provided. It includes technical background information and correlation with in vitro measurements of individual retinal metabolites. In a second part, clinical applications of fluorescence lifetime imaging and fluorescence lifetime features of selected retinal diseases such as Stargardt disease, age-related macular degeneration, choroideremia, central serous chorioretinopathy, macular holes, diabetic retinopathy, and retinal artery occlusion are discussed. Potential areas of use for fluorescence lifetime imaging ophthalmoscopy will be outlined at the end of this review.

Indexed as

Fluorescein AngiographyHumansOphthalmoscopyRetinaRetinal DiseasesFLIOFluorescence lifetimesFluorophoreFundus autofluorescenceMetabolismRetinal imaging

Identifiers

PMID28673870
PMCPMC7396320
OpenAlexW2734165961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.